Answers are grounded in this paper and cite their sources.
Inflammation is widely believed to play a central role in the pathogenesis of atherosclerosis and acute coronary events.1,2 Although treatments with proven benefits for secondary prevention of coronary artery disease (e.g., statins and aspirin) appear to have salutary effects on inflammation, the identification of an effective treatment specifically targeting inflammation has been elusive.3 The Canakinumab Antiinflammatory Thrombosis Outcomes Study (CANTOS) provided encouragement that targeting inflammation may be an effective treatment in chronic coronary artery disease. In CANTOS, canakinumab, a monoclonal antibody inhibiting interleukin-1β, reduced the level of high-sensitivity C-reactive protein and resulted in a modestly lower risk of the composite . . .
No takes yet. Share an insight, caveat, or question.
L. Kristin Newby (2019) conducted an editorial in Acute Myocardial Infarction. Canakinumab was evaluated.
Synapse has enriched 10 related papers. Consider them for comparative context: